Special Issue

Novel and Future Developments in Epigenetic Therapy for Cancer

Message from the Guest Editor

The alterations in the epigenetic landscape are considered to be a hallmark of cancer. Current research shows that large-scale reprogramming of epigenetic mechanism of cancer cells involves DNA methylation, histone modifications, dynamic assembly of chromatin remodeling complex, nucleosome localization and non-coding RNAs expression. Cancer cells often exhibit alterations in the enzymatic activity of epigenetic factors, showing aberrant modifications of histone and non-histone proteins which contribute to cancer progression. In recent years, continuous research efforts have resulted in the development of tailor-made cancer epigenetic therapy, which is now regarded as the future of precision medicine. Overall, a growing body of evidence indicates that SMYD3 is an essential epigenetic regulator that methylates histone and non-histone substrates, orchestrating protein–protein and protein–DNA interactions; however, its epigenetic role in cancer is not yet fully understood. This Special Issue aims to collate relevant papers, original research as well as reviews, that highlight the recent and future developments in epigenetic therapy for cancer.

Guest Editor

Dr. Paola Sanese
Medical Genetics, National Institute of Gastroenterology Saverio de Bellis, IRCCS Research Hospital, Castellana Grotte, 70013 Bari, Italy

Deadline for manuscript submissions

closed (15 October 2024)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/185330

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).

MDPI